Header Logo

Connection

Rajender Aparasu to Humans

Back to Details
This is a "connection" page, showing publications Rajender Aparasu has written about Humans.
Rajender Aparasu
Connection Strength
4.838
Humans
  1. Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
    View in: PubMed
    Score: 0.096
  2. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.096
  3. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.096
  4. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.095
  5. Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data. Pharmacotherapy. 2024 Oct; 44(10):782-793.
    View in: PubMed
    Score: 0.095
  6. Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease. Arch Gerontol Geriatr. 2025 Jan; 128:105629.
    View in: PubMed
    Score: 0.095
  7. Adverse effects associated with antipsychotic use in older adults. Expert Opin Drug Saf. 2024 Sep; 23(9):1157-1171.
    View in: PubMed
    Score: 0.094
  8. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.091
  9. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
    View in: PubMed
    Score: 0.091
  10. Application of machine learning in predicting survival outcomes involving real-world data: a scoping review. BMC Med Res Methodol. 2023 11 13; 23(1):268.
    View in: PubMed
    Score: 0.089
  11. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.088
  12. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
    View in: PubMed
    Score: 0.088
  13. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.086
  14. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data. J Manag Care Spec Pharm. 2023 May; 29(5):480-489.
    View in: PubMed
    Score: 0.086
  15. Machine learning methods to predict 30-day hospital readmission outcome among US adults with pneumonia: analysis of the national readmission database. BMC Med Inform Decis Mak. 2022 11 09; 22(1):288.
    View in: PubMed
    Score: 0.083
  16. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
    View in: PubMed
    Score: 0.081
  17. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
    View in: PubMed
    Score: 0.081
  18. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.079
  19. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
    View in: PubMed
    Score: 0.078
  20. Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Med. 2021 10 08; 22(10):2224-2234.
    View in: PubMed
    Score: 0.077
  21. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
    View in: PubMed
    Score: 0.077
  22. National surveys to evaluate prescribing practices: Methodological considerations. Res Social Adm Pharm. 2022 02; 18(2):2317-2324.
    View in: PubMed
    Score: 0.076
  23. Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016. Am J Cardiol. 2021 08 01; 152:168.
    View in: PubMed
    Score: 0.075
  24. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs Aging. 2021 07; 38(7):593-602.
    View in: PubMed
    Score: 0.075
  25. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021 08; 37(8):1303-1313.
    View in: PubMed
    Score: 0.075
  26. Application of machine learning in predicting hospital readmissions: a scoping review of the literature. BMC Med Res Methodol. 2021 05 06; 21(1):96.
    View in: PubMed
    Score: 0.075
  27. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
    View in: PubMed
    Score: 0.074
  28. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.074
  29. Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs Aging. 2021 04; 38(4):311-326.
    View in: PubMed
    Score: 0.074
  30. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry. 2021 05; 36(5):684-696.
    View in: PubMed
    Score: 0.073
  31. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. J Am Med Dir Assoc. 2021 06; 22(6):1300-1306.
    View in: PubMed
    Score: 0.072
  32. Anticholinergic medications and risk of dementia in older adults: Where are we now? Expert Opin Drug Saf. 2020 Oct; 19(10):1251-1267.
    View in: PubMed
    Score: 0.072
  33. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Adv Ther. 2020 08; 37(8):3584-3605.
    View in: PubMed
    Score: 0.071
  34. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.071
  35. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.070
  36. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676.
    View in: PubMed
    Score: 0.069
  37. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
    View in: PubMed
    Score: 0.069
  38. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
    View in: PubMed
    Score: 0.069
  39. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. J Psychiatr Res. 2019 10; 117:116-121.
    View in: PubMed
    Score: 0.066
  40. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Res Social Adm Pharm. 2020 03; 16(3):329-335.
    View in: PubMed
    Score: 0.066
  41. Documentation of asthma control and severity in pediatrics: analysis of national office-based visits. J Asthma. 2020 02; 57(2):205-216.
    View in: PubMed
    Score: 0.064
  42. Asthma Medication Prescribing Practices in Pediatric Office Visits. Clin Pediatr (Phila). 2019 04; 58(4):395-405.
    View in: PubMed
    Score: 0.064
  43. Acetylcholinesterase Inhibitors: Start Low or Risk Going Slow? J Am Geriatr Soc. 2018 09; 66(9):1663-1664.
    View in: PubMed
    Score: 0.062
  44. FRAX tool underestimates the risk of osteoporotic fractures in mental disorders. Evid Based Ment Health. 2018 05; 21(2):80.
    View in: PubMed
    Score: 0.060
  45. Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs Aging. 2017 09; 34(9):691-700.
    View in: PubMed
    Score: 0.058
  46. Atypical antipsychotic prescribing in elderly patients with depression. Res Social Adm Pharm. 2018 07; 14(7):645-652.
    View in: PubMed
    Score: 0.058
  47. The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Subst Use Misuse. 2017 08 24; 52(10):1266-1274.
    View in: PubMed
    Score: 0.056
  48. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
    View in: PubMed
    Score: 0.056
  49. Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. Am J Alzheimers Dis Other Demen. 2016 12; 31(8):678-686.
    View in: PubMed
    Score: 0.055
  50. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):857-863.
    View in: PubMed
    Score: 0.055
  51. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs Aging. 2016 10; 33(10):755-763.
    View in: PubMed
    Score: 0.055
  52. Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016 08; 5(5):461-73.
    View in: PubMed
    Score: 0.054
  53. Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. J Am Geriatr Soc. 2016 07; 64(7):1492-7.
    View in: PubMed
    Score: 0.053
  54. Functional Status of Elderly Nursing Home Residents With Parkinson's Disease. J Parkinsons Dis. 2016 06 02; 6(3):617-24.
    View in: PubMed
    Score: 0.053
  55. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017 Mar - Apr; 13(2):358-363.
    View in: PubMed
    Score: 0.052
  56. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry. 2016 06; 24(6):485-95.
    View in: PubMed
    Score: 0.052
  57. Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study. J Am Geriatr Soc. 2016 Feb; 64(2):394-400.
    View in: PubMed
    Score: 0.052
  58. Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy. 2016 Jan; 36(1):38-48.
    View in: PubMed
    Score: 0.052
  59. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
    View in: PubMed
    Score: 0.051
  60. Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
    View in: PubMed
    Score: 0.024
  61. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.024
  62. Patterns of gabapentinoid use among long-term opioid users. Prev Med. 2024 Aug; 185:108046.
    View in: PubMed
    Score: 0.023
  63. Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
    View in: PubMed
    Score: 0.023
  64. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.022
  65. Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
    View in: PubMed
    Score: 0.022
  66. How do we define high and low dose intensity of heart failure medications: a scoping review. BMC Cardiovasc Disord. 2023 09 27; 23(1):478.
    View in: PubMed
    Score: 0.022
  67. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.022
  68. Outpatient opioid prescribing by Alzheimer's diagnosis among older adults with pain in United States. BMC Geriatr. 2023 08 01; 23(1):465.
    View in: PubMed
    Score: 0.022
  69. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.022
  70. The median doses of beta-blockers among older adults with heart failure with reduced ejection fraction. J Am Geriatr Soc. 2023 10; 71(10):3322-3325.
    View in: PubMed
    Score: 0.022
  71. Medication Complexity Among Older Adults with HF: How Can We Assess Better? Drugs Aging. 2022 11; 39(11):851-861.
    View in: PubMed
    Score: 0.021
  72. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023 01; 359:114238.
    View in: PubMed
    Score: 0.021
  73. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
    View in: PubMed
    Score: 0.020
  74. Association Between Initial Opioid Prescription Duration and 30-Day Risk of Receiving Repeat Opioid Among Children. Acad Pediatr. 2023 03; 23(2):416-424.
    View in: PubMed
    Score: 0.020
  75. Healthcare Expenditure Associated With Polypharmacy in Older Adults With Cardiovascular Diseases. Am J Cardiol. 2022 04 15; 169:156-158.
    View in: PubMed
    Score: 0.020
  76. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.019
  77. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.017
  78. Consideration of Aggressive and Strategic Approaches to Address Declining Enrollment in US Pharmacy Schools. Am J Pharm Educ. 2019 08; 83(6):6959.
    View in: PubMed
    Score: 0.017
  79. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
    View in: PubMed
    Score: 0.016
  80. The association between geographic access to providers and the treatment quality of pediatric depression. J Affect Disord. 2019 06 15; 253:162-170.
    View in: PubMed
    Score: 0.016
  81. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
    View in: PubMed
    Score: 0.016
  82. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.016
  83. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
    View in: PubMed
    Score: 0.015
  84. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.015
  85. Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
    View in: PubMed
    Score: 0.015
  86. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.014
  87. Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
    View in: PubMed
    Score: 0.014
  88. Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis. 2016; 49(2):423-32.
    View in: PubMed
    Score: 0.013
  89. Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen. 2016 08; 31(5):395-404.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.